A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma.
Elizabeth I BuchbinderJustine V CohenGiuseppe TarantinoChristine G LianDavid R LiuRizwan HaqFrank Stephen HodiDonald P LawrenceAnita Giobbie-HurderDeborah KnoerzerRyan J SullivanPublished in: Cancer research communications (2024)
Uveal melanoma is a difficult to treat disease with minimal therapy options. The majority of uveal melanomas have mutations in GNAQ or GNA11 leading to activation of the MAPK pathway. Efforts to target MEK in uveal melanoma has had mixed results. This phase II trial of ERK inhibition with BVD-523 examined the potential role of this agent in uveal melanoma therapy.
Keyphrases
- signaling pathway
- phase ii study
- pi k akt
- skin cancer
- open label
- cell proliferation
- squamous cell carcinoma
- small cell lung cancer
- oxidative stress
- basal cell carcinoma
- stem cells
- randomized controlled trial
- clinical trial
- locally advanced
- quality improvement
- mesenchymal stem cells
- risk assessment
- climate change
- study protocol